Wall Street Goes Bullish on Two Biotech Stocks: INBX and MPLT
Stifel & Needham back INBX & MPLT: promising cancer & brain drugs, strong safety, big market potential.
/ 1659 items
#XY↓
Plus Therapeutics Stock Jumps After FDA Orphan Drug Win for Kids’ Rare Brain Tumors
Plus Therapeutics’ REYOBIQ gets FDA orphan drug status for rare kids’ brain tumors.
ANI Pharmaceuticals Stock Jumps After FDA OKs New Generic Heart Drug
ANI Pharma shares jump as it launches FDA-approved generic Monoket to prevent chest pain from heart disease.
Oscar Health CEO Buys $11.9 Million of Stock
Oscar Health CEO bought $11.9M in shares after stock payout, showing strong confidence. Shares jumped.
Stifel Sees 134% Upside in Summit Therapeutics as Ivonescimab Eyes $200B Market
Stifel rates Summit Therapeutics a Buy. Its new cancer drug looks promising, and strong trial results could send the stock much higher.
Insmed Discontinues Brensocatib HS Program After Phase 2b CEDAR Study Misses All Endpoints
Insmed’s HS drug failed to beat placebo in a mid-stage trial, though it was safe. Development for this condition has been stopped.